This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
CONCLUSIONS Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial.
Source: Diabetes Care - September 21, 2016 Category: Endocrinology Authors: Inzucchi, S. E.; Viscoli, C. M.; Young, L. H.; Furie, K. L.; Gorman, M.; Lovejoy, A. M.; Dagogo-Jack, S.; Ismail-Beigi, F.; Korytkowski, M. T.; Pratley, R. E.; Schwartz, G. G.; Kernan, W. N.; for the IRIS Trial Investigators Tags: Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research